DNA · XBRL financial data

Ginkgo Bioworks Holdings financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (DNA's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	314	478	251	227	170
Research and development	1,150	1,053	581	424	244
General and administrative	863	1,430	385	246	183
Total operating expenses	2,142	2,687	1,116	787	485
Other operating income (expense)	(2)	8	9	4	(5)
Operating income (loss)	(1,828)	(2,209)	(864)	(560)	(315)
Interest expense	2	0	0	0	0
Other income (expense)	(10)	88	(29)	12	2
Income tax expense (benefit)	(1)	(15)	(0)	(0)	(1)
Net income (loss)	(1,830)	(2,105)	(893)	(547)	(313)
Earnings per share, basic‡ USD per share	(54.00)	(50.00)	(18.40)	(10.54)	(5.64)
Earnings per share, diluted‡ USD per share	(55.60)	(50.00)	(18.40)	(10.54)	(5.64)
Weighted average shares, basic‡ millions of shares	34	42	49	52	55
Weighted average shares, diluted‡ millions of shares	34	42	49	52	55

‡ Per-share figures and share counts are adjusted for the 1-for-40 stock split (August 2024); filings made before it reported them unadjusted.

Fiscal years (DNA's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1,550	1,316	944	562	167
Marketable securities	—	—	—	0	255
Accounts receivable	132	81	17	22	24
Inventory	3	4	0	—	—
Prepaid and other current assets	34	47	40	19	25
Total current assets	1,723	1,450	1,002	603	472
Property and equipment, net	146	315	188	204	168
Right-of-use asset	0	401	207	394	361
Goodwill	21	60	49	0	—
Total assets	2,071	2,539	1,665	1,377	1,120
Accounts payable	8	10	9	14	11
Accrued liabilities	93	115	—	—	—
Total current liabilities	135	173	164	107	96
Lease liability, non-current	0	413	222	439	417
Total liabilities	504	803	568	661	611
Accumulated deficit	(2,298)	(4,398)	(5,291)	(5,838)	(6,150)
Total stockholders' equity	1,505	1,736	1,097	716	509
Total liabilities and equity	2,071	2,539	1,665	1,377	1,120
Common shares outstanding (cover page)‡ millions of shares	40	47	50	54	58

‡ Per-share figures and share counts are adjusted for the 1-for-40 stock split (August 2024); filings made before it reported them unadjusted.

Fiscal years (DNA's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(1,830)	(2,105)	(893)	(547)	(313)
Stock-based compensation	1,606	1,931	230	112	82
Net cash from operating activities	(254)	(252)	(296)	(320)	(171)
Purchases of property and equipment	57	52	41	63	8
Net cash from investing activities	(73)	(67)	(81)	(62)	(240)
Proceeds from issuing common stock	—	—	0	0	19
Proceeds from issuing equity	15	40	—	—	—
Net cash from financing activities	1,534	95	(3)	(2)	18
Net change in cash	1,207	(223)	(380)	(384)	(393)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Ginkgo Bioworks Holdings	85	20	(44)*	63.7M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Xencor	60	117	2.6*	75.0M	—	Q3 FY26 10-QSep 30, 2026
Evolus	42	78	(1.9)*	66.2M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
Savara	42	not reported	(30)*	205.5M	5.8 quarters	Q2 FY26 10-QJun 30, 2026
Opko Health	384	65	(36)*	742.5M	10.8 quarters	Q3 FY26 10-QSep 30, 2026
Iovance Biotherapeutics	58	121	(4.5)*	462.7M	7.3 quarters	Q3 FY26 10-QSep 30, 2026
Elite Pharmaceuticals	39	32	10	1.1B	—	Q1 FY27 10-QJun 30, 2026
Trevi Therapeutics	54	not reported	(17)*	142.5M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
Stoke Therapeutics	107	11	(63)*	65.4M	5.2 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 7, 2026, 12:54 PM ET. The filing on SEC.gov is the record.